

Genetic alterations of JAK/STAT cascade and histone methylase in nasal type lymphoma

Oncotarget

6, 17764-17776

DOI: [10.18632/oncotarget.3776](https://doi.org/10.18632/oncotarget.3776)

Citation Report

#	ARTICLE	IF	CITATIONS
2	New developments in the pathology of malignant lymphoma: a review of literature published from January 2015 to April 2015. <i>Journal of Hematopathology</i> , 2015, 8, 71-79.	0.2	2
3	Current Management Concepts: Primary Central Nervous System Lymphoma, Natural Killer T-Cell Lymphoma Nasal Type, and Post-transplant Lymphoproliferative Disorder. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016, 35, e354-e366.	1.8	4
4	Successful Treatment of Genetically Profiled Pediatric Extranodal NK/T-Cell Lymphoma Targeting Oncogenic <i>STAT3</i> Mutation. <i>Pediatric Blood and Cancer</i> , 2016, 63, 727-730.	0.8	7
5	EZH2 phosphorylation by JAK3 mediates a switch to noncanonical function in natural killer/T-cell lymphoma. <i>Blood</i> , 2016, 128, 948-958.	0.6	110
6	Frequent <i>BCOR</i> aberrations in extranodal NK/T-Cell lymphoma, nasal type. <i>Genes Chromosomes and Cancer</i> , 2016, 55, 460-471.	1.5	97
7	Diagnosis and management of extranodal NK/T cell lymphoma nasal type. <i>Expert Review of Hematology</i> , 2016, 9, 861-871.	1.0	71
8	Tyrosine kinase 2 – Surveillant of tumours and bona fide oncogene. <i>Cytokine</i> , 2017, 89, 209-218.	1.4	45
9	Macrophage inflammatory protein 1 alpha (MIP-1 α) may be associated with poor outcome in patients with extranodal NK/T-cell lymphoma. <i>Hematological Oncology</i> , 2017, 35, 310-316.	0.8	14
10	The diagnosis and management of NK/T-cell lymphomas. <i>Journal of Hematology and Oncology</i> , 2017, 10, 85.	6.9	233
11	Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape. <i>European Journal of Cancer</i> , 2017, 81, 116-129.	1.3	443
12	EBV-negative Aggressive NK-cell Leukemia/Lymphoma. <i>American Journal of Surgical Pathology</i> , 2017, 41, 67-74.	2.1	59
13	EBV-negative aggressive NK-cell leukemia/lymphoma: a clinical and pathological study from a single institution. <i>Modern Pathology</i> , 2017, 30, 1100-1115.	2.9	30
14	Novel JAK3-Activating Mutations in Extranodal NK/T-Cell Lymphoma, Nasal Type. <i>American Journal of Pathology</i> , 2017, 187, 980-986.	1.9	44
15	Internal deletion of BCOR reveals a tumor suppressor function for BCOR in T lymphocyte malignancies. <i>Journal of Experimental Medicine</i> , 2017, 214, 2901-2913.	4.2	43
16	Novel High-grade Endometrial Stromal Sarcoma. <i>American Journal of Surgical Pathology</i> , 2017, 41, 12-24.	2.1	115
17	Exome sequencing identifies recurrent <i>BCOR</i> alterations and the absence of <i>KLF2</i> , <i>TNFAIP3</i> and <i>MYD88</i> mutations in splenic diffuse red pulp small B-cell lymphoma. <i>Haematologica</i> , 2017, 102, 1758-1766.	1.7	54
18	Distinct subtype distribution and somatic mutation spectrum of lymphomas in East Asia. <i>Current Opinion in Hematology</i> , 2017, 24, 367-376.	1.2	9
19	Beyond first-line non-anthracycline-based chemotherapy for extranodal NK/T-cell lymphoma: clinical outcome and current perspectives on salvage therapy for patients after first relapse and progression of disease. <i>Annals of Oncology</i> , 2017, 28, 2199-2205.	0.6	54

#	ARTICLE	IF	CITATIONS
20	Aggressive natural killer-cell leukemia—mutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic target. <i>Nature Communications</i> , 2018, 9, 1567.	5.8	107
21	Oncogenic activation of JAK3-STAT signaling confers clinical sensitivity to PRN371, a novel selective and potent JAK3 inhibitor, in natural killer/T-cell lymphoma. <i>Leukemia</i> , 2018, 32, 1147-1156.	3.3	41
22	Novel findings from the Asian Lymphoma Study Group: focus on T and NK-cell lymphomas. <i>International Journal of Hematology</i> , 2018, 107, 413-419.	0.7	9
23	Hepatosplenic T-cell Lymphoma: a review of clinicopathologic features, pathogenesis, and prognostic factors. <i>Human Pathology</i> , 2018, 74, 5-16.	1.1	77
24	Inhibition of histone H3K27 demethylases selectively modulates inflammatory phenotypes of natural killer cells. <i>Journal of Biological Chemistry</i> , 2018, 293, 2422-2437.	1.6	72
25	Genetic convergence of rare lymphomas. <i>Current Opinion in Hematology</i> , 2018, 25, 307-314.	1.2	2
26	New tumor entities in the 4th edition of the World Health Organization classification of head and neck tumors: Nasal cavity, paranasal sinuses and skull base. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2018, 472, 315-330.	1.4	97
27	Epstein-Barr virus-negative extranodal natural killer cell lymphoma harbouring a <i>KDM6A</i> mutation. <i>Hematological Oncology</i> , 2018, 36, 328-335.	0.8	8
28	JAK inhibitors for the treatment of myeloproliferative neoplasms and other disorders. <i>F1000Research</i> , 2018, 7, 82.	0.8	126
29	Emerging role of noncanonical polycomb repressive complexes in normal and malignant hematopoiesis. <i>Experimental Hematology</i> , 2018, 68, 10-14.	0.2	15
30	Bcor insufficiency promotes initiation and progression of myelodysplastic syndrome. <i>Blood</i> , 2018, 132, 2470-2483.	0.6	36
31	Extranodal NK/T-cell lymphoma: Updates in biology and management strategies. <i>Best Practice and Research in Clinical Haematology</i> , 2018, 31, 315-321.	0.7	32
32	Oncogenic activation of the STAT3 pathway drives PD-L1 expression in natural killer/T-cell lymphoma. <i>Blood</i> , 2018, 132, 1146-1158.	0.6	218
33	EBV-Positive Lymphoproliferations of B- T- and NK-Cell Derivation in Non-Immunocompromised Hosts. <i>Pathogens</i> , 2018, 7, 28.	1.2	88
34	The Genomics and Molecular Biology of Natural Killer/T-Cell Lymphoma: Opportunities for Translation. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1931.	1.8	28
35	The 2017 WHO update on mature T and natural killer (NK) cell neoplasms. <i>International Journal of Laboratory Hematology</i> , 2018, 40, 97-103.	0.7	51
36	Frequent Mutations in Natural Killer/T Cell Lymphoma. <i>Cellular Physiology and Biochemistry</i> , 2018, 49, 1-16.	1.1	29
37	Epstein-Barr Virus and Cancer. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2019, 14, 29-53.	9.6	303

#	ARTICLE	IF	CITATIONS
38	The Global Landscape of EBV-Associated Tumors. <i>Frontiers in Oncology</i> , 2019, 9, 713.	1.3	289
39	Somatic mutations in <i>KMT2D</i> and <i>TET2</i> associated with worse prognosis in Epstein-Barr virus-associated T or natural killer-cell lymphoproliferative disorders. <i>Cancer Biology and Therapy</i> , 2019, 20, 1319-1327.	1.5	22
40	Intravascular NK/T-cell lymphoma: clinicopathological and integrated molecular analysis of two cases provides a clue to disease pathogenesis. <i>Journal of Clinical Pathology</i> , 2019, 72, 642-646.	1.0	11
41	Clonal Evolution of MEK/MAPK Pathway Activating Mutations in a Metastatic Colorectal Cancer Case. <i>Anticancer Research</i> , 2019, 39, 5867-5877.	0.5	7
42	Recent advances in the diagnosis and treatment of natural killer/T-cell lymphomas. <i>Expert Review of Hematology</i> , 2019, 12, 927-935.	1.0	21
43	Recurrent GNAQ mutation encoding T96S in natural killer/T cell lymphoma. <i>Nature Communications</i> , 2019, 10, 4209.	5.8	25
44	Genome profiling revealed the activation of IL2RG/JAK3/STAT5 in peripheral T-cell lymphoma expressing the ITK-SYK fusion gene. <i>International Journal of Oncology</i> , 2019, 55, 1077-1089.	1.4	8
45	Mature (non-anaplastic, non-cutaneous) T-cell lymphomas in children, adolescents and young adults: state of the science. <i>British Journal of Haematology</i> , 2019, 185, 418-435.	1.2	9
46	Treatment and prognosis of mature (non-anaplastic) T and NK cell lymphomas in childhood, adolescents, and young adults. <i>British Journal of Haematology</i> , 2019, 185, 1086-1098.	1.2	2
47	Transcriptomic Abnormalities in Epstein Barr Virus Associated T/NK Lymphoproliferative Disorders. <i>Frontiers in Pediatrics</i> , 2019, 6, 405.	0.9	12
48	BCOR involvement in cancer. <i>Epigenomics</i> , 2019, 11, 835-855.	1.0	113
49	Primary intestinal NK-cell lymphoma, EBV-negative: A case report and literature review. <i>Human Pathology: Case Reports</i> , 2019, 17, 200303.	0.2	2
50	NK/T-cell lymphomas. <i>Best Practice and Research in Clinical Haematology</i> , 2019, 32, 253-261.	0.7	41
51	JAK3/STAT3 oncogenic pathway and PRDM1 expression stratify clinicopathologic features of extranodal NK/T-cell lymphoma, nasal type. <i>Oncology Reports</i> , 2019, 41, 3219-3232.	1.2	24
52	Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type: Basic Science and Clinical Progress. <i>Frontiers in Pediatrics</i> , 2019, 7, 141.	0.9	73
54	Epstein-Barr Virus-Associated T and NK-Cell Lymphoproliferative Diseases. <i>Frontiers in Pediatrics</i> , 2019, 7, 71.	0.9	86
55	Pathogenesis and biomarkers of natural killer T cell lymphoma (NKTL). <i>Journal of Hematology and Oncology</i> , 2019, 12, 28.	6.9	27
56	Molecular pathogenic pathways in extranodal NK/T cell lymphoma. <i>Journal of Hematology and Oncology</i> , 2019, 12, 33.	6.9	82

#	ARTICLE	IF	CITATIONS
57	Pathology and diagnosis of non-mycosis fungoides CTCL. , 2019, , .		0
58	Targeting the JAK/STAT Pathway in T Cell Lymphoproliferative Disorders. Current Hematologic Malignancy Reports, 2019, 14, 570-576.	1.2	18
59	Aberrant differential expression of EZH2 and H3K27me3 in extranodal NK/T-cell lymphoma, nasal type, is associated with disease progression and prognosis. Human Pathology, 2019, 83, 166-176.	1.1	23
60	T-cell large granular lymphocyte leukemia transformation into aggressive T-cell lymphoma: a report of two cases with molecular characterization. Haematologica, 2019, 104, e117-e120.	1.7	5
61	Molecular and Genomic Landscape of Peripheral T-Cell Lymphoma. Cancer Treatment and Research, 2019, 176, 31-68.	0.2	23
62	MiRNA-155 regulates lymphangiogenesis in natural killer/T-cell lymphoma by targeting BRG1. Cancer Biology and Therapy, 2019, 20, 31-41.	1.5	32
63	Gastrointestinal T- and NK-cell lymphomas and indolent lymphoproliferative disorders. Seminars in Diagnostic Pathology, 2020, 37, 11-23.	1.0	23
65	Epstein - Barr virus positive T and NK-cell lymphoproliferations: Morphological features and differential diagnosis. Seminars in Diagnostic Pathology, 2020, 37, 32-46.	1.0	34
66	Targeting epigenetic regulators in the treatment of T-cell lymphoma. Expert Review of Hematology, 2020, 13, 127-139.	1.0	8
67	Mutational profile and EBV strains of extranodal NK/T-cell lymphoma, nasal type in Latin America. Modern Pathology, 2020, 33, 781-791.	2.9	42
69	Molecular insights into pathogenesis and targeted therapy of peripheral T cell lymphoma. Experimental Hematology and Oncology, 2020, 9, 30.	2.0	15
70	Genetic manipulation of primary human natural killer cells to investigate the functional and oncogenic roles of PRDM1. Haematologica, 2020, 106, haematol.2020.254276.	1.7	5
71	Aggressive NK Cell Leukemia: Current State of the Art. Cancers, 2020, 12, 2900.	1.7	17
72	An Enteropathy-like Indolent NK-Cell Proliferation Presenting in the Female Genital Tract. American Journal of Surgical Pathology, 2020, 44, 561-565.	2.1	11
73	Extranodal NK/T-Cell Lymphomas: The Role of Natural Killer Cells and EBV in Lymphomagenesis. International Journal of Molecular Sciences, 2020, 21, 1501.	1.8	15
74	Peripheral T cell lymphomas: from the bench to the clinic. Nature Reviews Cancer, 2020, 20, 323-342.	12.8	74
75	Frequent mutations in HLA and related genes in extranodal NK/T cell lymphomas. Leukemia and Lymphoma, 2021, 62, 95-103.	0.6	12
76	Extranodal Natural Killer/T-cell Lymphoma, Nasal Type: Diagnosis and Treatment. HemaSphere, 2021, 5, e523.	1.2	15

#	ARTICLE	IF	CITATIONS
77	Dissecting the Role of BET Bromodomain Proteins BRD2 and BRD4 in Human NK Cell Function. <i>Frontiers in Immunology</i> , 2021, 12, 626255.	2.2	15
79	Extranodal NK/T cell lymphoma, nasal type: An updated overview. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 159, 103237.	2.0	36
80	EBV and the Pathogenesis of NK/T Cell Lymphoma. <i>Cancers</i> , 2021, 13, 1414.	1.7	31
81	EBV-Associated Lymphoproliferative Disorders. <i>Clinical Pediatric Hematology-Oncology</i> , 2021, 28, 14-27.	0.0	2
82	EGR1 as a potential marker of prognosis in extranodal NK/T-cell lymphoma. <i>Scientific Reports</i> , 2021, 11, 10342.	1.6	4
83	<i>BCOR</i> gene alterations in hematologic diseases. <i>Blood</i> , 2021, 138, 2455-2468.	0.6	18
84	Untwining Anti-Tumor and Immunosuppressive Effects of JAK Inhibitors—A Strategy for Hematological Malignancies?. <i>Cancers</i> , 2021, 13, 2611.	1.7	15
85	Epstein-Barr Virus-Associated T- and NK-Cell Lymphoproliferative Diseases: A Review of Clinical and Pathological Features. <i>Cancers</i> , 2021, 13, 3315.	1.7	10
86	Diagnostic approach to T- and NK-cell lymphoproliferative disorders in the gastrointestinal tract. <i>Seminars in Diagnostic Pathology</i> , 2021, 38, 21-30.	1.0	3
87	Towards Next Generation Biomarkers in Natural Killer/T-Cell Lymphoma. <i>Life</i> , 2021, 11, 838.	1.1	4
88	The Acetyltransferase KAT5 Inhibitor NU 9056 Promotes Apoptosis and Inhibits JAK2/STAT3 Pathway in Extranodal NK/T Cell Lymphoma. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2022, 22, 1530-1540.	0.9	2
89	The mutation of <i>BCOR</i> is highly recurrent and oncogenic in mature T-cell lymphoma. <i>BMC Cancer</i> , 2021, 21, 82.	1.1	9
90	Gene alterations in epigenetic modifiers and JAK-STAT signaling are frequent in breast implant-associated ALCL. <i>Blood</i> , 2020, 135, 360-370.	0.6	80
91	Angiocentric Centrofacial Lymphoma as a Challenging Diagnosis in an Elderly Man. <i>American Journal of Case Reports</i> , 2019, 20, 412-418.	0.3	1
92	A neutralized human LMP1-IgG inhibits ENKTL growth by suppressing the JAK3/STAT3 signaling pathway. <i>Oncotarget</i> , 2017, 8, 10954-10965.	0.8	13
93	Genetic landscape of T- and NK-cell post-transplant lymphoproliferative disorders. <i>Oncotarget</i> , 2016, 7, 37636-37648.	0.8	46
94	Pathogenic Impacts of Dysregulated Polycomb Repressive Complex Function in Hematological Malignancies. <i>International Journal of Molecular Sciences</i> , 2021, 22, 74.	1.8	15
95	Molecular Testing of Lymphoproliferative Disorders: Current Status and Perspectives. <i>Journal of Pathology and Translational Medicine</i> , 2017, 51, 224-241.	0.4	12

#	ARTICLE	IF	CITATIONS
96	Mutational Analysis of Extranodal NK/T-Cell Lymphoma Using Targeted Sequencing with a Comprehensive Cancer Panel. <i>Genomics and Informatics</i> , 2016, 14, 78.	0.4	17
97	Janus Kinase Signaling: Oncogenic Criminal of Lymphoid Cancers. <i>Cancers</i> , 2021, 13, 5147.	1.7	4
98	Peripheral T-Cell Lymphomas. , 2018, , 306-339.e3.		2
99	Lymphomas. , 2020, , 253-315.		0
100	Primary breast CD20-positive extranodal NK/T cell lymphoma with stomach involvement: a case report and literature review. <i>Diagnostic Pathology</i> , 2021, 16, 103.	0.9	2
101	EBV-Driven Lymphoproliferative Disorders and Lymphomas of the Gastrointestinal Tract: A Spectrum of Entities with a Common Denominator (Part 3). <i>Cancers</i> , 2021, 13, 6021.	1.7	3
102	The Pathologic and Genetic Characteristics of Extranodal NK/T-Cell Lymphoma. <i>Life</i> , 2022, 12, 73.	1.1	14
103	Recent Advances in the Diagnosis and Treatment of Natural Killer Cell Malignancies. <i>Cancers</i> , 2022, 14, 597.	1.7	4
104	Clinicopathologic and Genetic Features of Primary T-cell Lymphomas of the Central Nervous System. <i>American Journal of Surgical Pathology</i> , 2022, 46, 486-497.	2.1	2
105	Identification and Targeting of the Developmental Blockade in Extranodal Natural Killer/T-cell Lymphoma. <i>Blood Cancer Discovery</i> , 2022, 3, 154-169.	2.6	8
106	Recent advances in T-cell lymphoid neoplasms. <i>Experimental Hematology</i> , 2022, 106, 3-18.	0.2	9
107	Update on Molecular Diagnosis in Extranodal NK/T-Cell Lymphoma and Its Role in the Era of Personalized Medicine. <i>Diagnostics</i> , 2022, 12, 409.	1.3	5
108	Tumor Immune Microenvironment in Lymphoma: Focus on Epigenetics. <i>Cancers</i> , 2022, 14, 1469.	1.7	6
109	VÃas moleculares patogÃ©nicas del linfoma T/NK extranodal de tipo nasal asociadas con virus de Epstein Barr: RevisiÃ³n narrativa. <i>Ciencia, TecnologÃa Y Salud</i> , 2021, 8, 245-259.	0.0	0
110	The identification of gene signatures in patients with extranodal NK/T-cell lymphoma from a pair of twins. <i>BMC Cancer</i> , 2021, 21, 1303.	1.1	3
112	Novel enzyme-sensitive poly-tioxolone membranes for peritendinous anti-adhesion. <i>Composites Part B: Engineering</i> , 2022, 238, 109904.	5.9	3
113	The Effect of Chronic Rhinosinusitis on the Staging and Prognosis of Extranodal Natural Killer/T-Cell Lymphoma: A Single-Center Retrospective Analysis. <i>Frontiers in Oncology</i> , 2022, 12, 878559.	1.3	1
114	Deregulated JAK3 mediates growth advantage and hemophagocytosis in extranodal nasal-type natural killer/T cell lymphoma. <i>Haematologica</i> , 2022, , .	1.7	1

#	ARTICLE	IF	CITATIONS
115	Cellular Origins and Pathogenesis of Gastrointestinal NK- and T-Cell Lymphoproliferative Disorders. <i>Cancers</i> , 2022, 14, 2483.	1.7	2
116	Genomic profiling identifies distinct genetic subtypes in extra-nodal natural killer/T-cell lymphoma. <i>Leukemia</i> , 2022, 36, 2064-2075.	3.3	15
117	A genomicâ€augmented multivariate prognostic model for the survival of naturalâ€killer/Tâ€cell lymphoma patients from an international cohort. <i>American Journal of Hematology</i> , 2022, 97, 1159-1169.	2.0	4
118	Kayadiol exerted anticancer effects through p53-mediated ferroptosis in NKTCL cells. <i>BMC Cancer</i> , 2022, 22, .	1.1	16
119	The Multifaceted Role of STAT3 in NK-Cell Tumor Surveillance. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	11
120	Genetic and immunohistochemical profiling of NK/T-cell lymphomas reveals prognostically relevant <i>BCOR</i> -MYC association. <i>Blood Advances</i> , 2023, 7, 178-189.	2.5	6
121	Genomic profiling for clinical decision making in lymphoid neoplasms. <i>Blood</i> , 2022, 140, 2193-2227.	0.6	63
122	New concepts in EBV-associated B, T, and NK cell lymphoproliferative disorders. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2023, 482, 227-244.	1.4	34
123	Genetics Abnormalities with Clinical Impact in Primary Cutaneous Lymphomas. <i>Cancers</i> , 2022, 14, 4972.	1.7	6
124	Extranodal natural killer/T-cell lymphoma: an overview on pathology and clinical management. <i>Seminars in Hematology</i> , 2022, , .	1.8	3
125	High-dose extended-field radiotherapy plus chemotherapy improved survival in extranodal NK/T-cell lymphoma in a real-life setting: results from the multicenter T-Cell Brazil Project. <i>Scientific Reports</i> , 2022, 12, .	1.6	2
126	Aberrant JAK-STAT signaling-mediated chromatin remodeling impairs the sensitivity of NK/T-cell lymphoma to chidamide. <i>Clinical Epigenetics</i> , 2023, 15, .	1.8	3
127	In-depth circulating tumor DNA sequencing for prognostication and monitoring in natural killer/T-cell lymphomas. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	3
128	SWI/SNF complexes in hematological malignancies: biological implications and therapeutic opportunities. <i>Molecular Cancer</i> , 2023, 22, .	7.9	12
129	Rational Targets of Therapy in Extranodal NK/T-Cell Lymphoma. <i>Cancers</i> , 2023, 15, 1366.	1.7	3
136	Molecular Pathology of Head and Neck Tumors. , 2023, , 493-516.		0